NVS - Cancer Research Highlight: Astellas Takes Us Into A New Generation Of Therapy For AML
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage.
If you've followed my news coverage for the week, then I imagine you're getting a little bit bored of acute myeloid leukemia ((AML)) stuff. There has been an absolute blitz of approvals and other news coming out for this form of leukemia recently, including the following: